The goal of this presentation is to better understand the contribution of aldosterone and its receptor, the mineralocorticoid receptor, to the pathophysiology of cardiorenal injury. Excess aldosterone/mineralocorticoid receptor activity is common in hypertension, obesity (especially obesity with metabolic syndrome components), heart failure, diabetes and persons with HIV. Preclinical and clinical studies demonstrate that blocking the mineralocorticoid receptor or reducing excess aldosterone reduces renal injury and improves arterial inflammation and coronary microvascular dysfunction, key mechanisms underlying cardiovascular disease.